US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

Story overview

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

This overview uses information supplied by ARY News. TenderWatch links to the publisher’s report and does not reproduce the full article.